Scott L Burrows sold $2.3M of SYRE
Chief Financial Officer at Spyre Therapeutics, Inc.. 25,000 shares at an average of $90.47, traded Sep 30, 2026, filed Oct 2, 2026.
Score components
- +22RoleCFO
- +25Trade size$2.3M at market
- +10Share of holdings soldSold 26% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001636282-26-000117, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | MOption exercise Common Stock10b5-1 | +17,500 | $14.50 | $254k | 97,262 | 10 d ago |
| Sep 30, 2026 | SOpen-market sale Common Stock10b5-1 | -17,500 | $89.89 | $1.6M | 79,762 | 10 d ago |
| Oct 1, 2026 | MOption exercise Common Stock10b5-1 | +7,500 | $14.50 | $109k | 87,262 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -600 | $89.07 | $53k | 86,662 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,500 | $90.27 | $135k | 85,162 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -2,100 | $91.92 | $193k | 83,062 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -3,071 | $92.95 | $285k | 79,991 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -229 | $93.57 | $21k | 79,762 | 10 d ago |
| Sep 30, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -17,500 | $0.00 | $0 | 319,857 | 10 d ago |
| Oct 1, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,500 | $0.00 | $0 | 312,357 | 10 d ago |
Related signals
Other insiders at Spyre Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.6M 28,933 shares | -91% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.4M 15,000 shares | -3% | |
| 32Weak | Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $2.3M 25,732 shares | -24% | |
| 40Moderate | Spyre Therapeutics, Inc. | Heidy King-Jones See Remarks | $2.5M 28,399 shares | -92% | |
| 45Moderate | Spyre Therapeutics, Inc. | Cameron Turtle Chief Executive Officer | $1.3M 15,000 shares | -3% | |
| 41Moderate | SYREsell Spyre Therapeutics, Inc. | Scott L Burrows Chief Financial Officer | $300k 18,428 shares | -16% | |
| 13Weak | Spyre Therapeutics, Inc. | Jeffrey W. Albers director | $246k 6,700 shares | -20% | |
| 0Weak | Spyre Therapeutics, Inc. | Jeffrey W. Albers director | $11k 300 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.